paroxysmal nocturnal hemoglobinuria


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.
Related to paroxysmal nocturnal hemoglobinuria: Paroxysmal cold hemoglobinuria

hemoglobinuria

 [he″mo-glo″bĭ-nu´re-ah]
the presence of free hemoglobin in the urine. adj., adj hemoglobinu´ric.
march hemoglobinuria hemolysis caused by repeated uncushioned shocks or trauma to some body part, such as in some soldiers on long marches, in marathon runners, and in karate practitioners.
paroxysmal cold hemoglobinuria an autoimmune or postviral disease in which there is a biphasic IgG antibody directed against the P blood group antigen. It is marked by episodes of hemoglobinemia and hemoglobinuria after exposure to cold and is detected by the Donath-Landsteiner test. The condition is treated with prednisone and cyclophosphamide and by protection from exposure to cold.
paroxysmal nocturnal hemoglobinuria (PNH) an acquired blood cell abnormality with proliferation of abnormal red blood cells (PNH cells) that are readily hemolyzed by complement, and episodes of severe hemolysis and thrombosis, particularly of the hepatic veins. It is detected by the ham test. Treatment is with androgens or prednisone and, during thrombotic episodes, with heparin.

par·ox·ys·mal noc·tur·nal he·mo·glo·bi·nu·ri·a

an infrequent disorder with insidious onset (usually in the third or fourth decade) and chronic course, characterized by episodes of hemolytic anemia, hemoglobinuria (chiefly at night), pallor, icterus or bronzing of the skin, a moderate degree of splenomegaly, and sometimes hepatomegaly; red blood cells are usually macrocytic and vary considerably in size, but there is no evidence of spherocytosis, erythrophagocytosis, or abnormal leukocytes. The disorder is a result of an abnormality of the red blood cell membrane, which makes the red blood cell unusually sensitive to lysis by complement.

paroxysmal nocturnal hemoglobinuria

n.
A rare hemolytic disorder caused by an acquired genetic mutation affecting hematopoietic stem cells, characterized by hemolytic anemia and hemoglobinuria, primarily at night.

paroxysmal nocturnal hemoglobinuria

An acquired hemolytic disease, due to proliferation of an abnormal clone(s) of myeloid stem cells, the progeny of which are susceptible to complement-mediated membrane damage and hemolysis–CMH Clinical Thromboses, ↑ infections; PNH may evolve into aplastic or sideroblastic anemia, myelofibrosis, AML Lab Leukopenia, thrombocytopenia, dimorphic RBC population, iron-deficiency, ↓ leukocyte alk phos, ↓ RBC acetylcholinesterase, altered properdin–alternate pathway of complement lysis, hemoglobinuria, hemosiderinuria, positive Ham test, positive sucrose lysis test; negative direct Coombs' test, ↑ susceptibility of RBCs to CMH

par·ox·ys·mal noc·tur·nal he·mo·glo·bi·nu·ri·a

(PNH) (par'ok-siz'măl nok-tŭr'năl hē'mŏ-glō'bi-nyūr'ē-ă)
A hemolytic anemia in which the red blood cell membrane is abnormal, rendering the cell more susceptible to hemolysis by complement. The membrane defects include a lack of decay-accelerating factor (DAF) and C8 binding protein (C8bp) due to lack of glycosyl phosphatidyl inositol (GPI). GPI is a membrane glycolipid that attaches proteins to the cell membrane. Hemolysis is intravascular and intermittent, characterized by passage of reddish urine.

Paroxysmal nocturnal hemoglobinuria (PNH)

A rare complement disorder characterized by episodes of red blood cell destruction (hemolysis) and blood in the urine (hemoglobinuria) that is worse at night.

Marchiafava,

Ettore, Italian pathologist, 1847-1935.
Marchiafava syndrome - Synonym(s): Marchiafava-Bignami syndrome
Marchiafava-Bignami disease - a disorder consisting of demyelination of the corpus callosum and cortical laminar necrosis involving the frontal and temporal lobes. Synonym(s): Marchiafava syndrome
Marchiafava-Micheli anemia - Synonym(s): Marchiafava-Micheli syndrome
Marchiafava-Micheli syndrome - an infrequent disorder with insidious onset and chronic course, characterized by episodes of hemolytic anemia, hemoglobinuria, pallor, icterus or bronzing of the skin, a moderate degree of splenomegaly, and sometimes hepatomegaly. Synonym(s): Marchiafava-Micheli anemia; paroxysmal nocturnal hemoglobinuria
References in periodicals archive ?
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Country Outlook (Revenue, USD Million, 2017 - 2025)
Roth, "Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab," Annals of Hematology, vol.
Miller, "Paroxysmal nocturnal hemoglobinuria (PNH) and pregnancy in the era of eculizumab," Leukemia Research, vol.
* The report reviews key players involved in the therapeutics development for Paroxysmal Nocturnal Hemoglobinuria and enlists all their major and minor projects
Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria. J Thromb Haemost 2012; 10:1-10.
Soliris is the first product approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the United States and Europe.
Reported causes of intravascular hemolysis that result in renal hemosiderosis are mechanical hemolysis (ie, from a dysfunctional valve replacement), paroxysmal nocturnal hemoglobinuria, and sickle cell anemia.
* During April 2007, Alexion initiated commercial sales of SolirisTM (eculizumab) in the United States for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disorder.
NAP activity is substantially decreased in hematopoietic stem cell disorders such as CML and paroxysmal nocturnal hemoglobinuria (2).
Alexion Pharmaceuticals, Inc., Cheshire, CT, announced the FDA and the European Agency for the Evaluation of Medicinal Products have granted the company orphan drug status for its investigative compound eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), an acquired genetic disorder.
Alexion Pharmaceuticals announced that the European Commission has approved ULTOMIRIS - the first and only long-acting C5 complement inhibitor administered every eight weeks - for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria with hemolysis with clinical symptoms indicative of high disease activity, and also for adult patients who are clinically stable after having been treated with SOLIRIS for at least the past six months.

Full browser ?